Women Are Replacing Old Breast Implants With New

Publication
Article
OncologyONCOLOGY Vol 13 No 12
Volume 13
Issue 12

Results of a study conducted by the American Society of Plastic and Reconstructive Surgeons (ASPRS) showed that 84% of women who have had their breast implants removed have replaced them with new implants. In 1998, 32,262 women with breast augmentation had their breast implants removed, and 27,320 of them opted for new implants.

Results of a study conducted by the American Society of Plastic and Reconstructive Surgeons (ASPRS) showed that 84% of women who have had their breast implants removed have replaced them with new implants. In 1998, 32,262 women with breast augmentation had their breast implants removed, and 27,320 of them opted for new implants.

Breast implant removals have increased 76% since 1992, with only 4% of patients having them removed due to their concern over the safety of breast implants. “The increase in breast implant removals most likely reflects implants that were inserted prior to 1992,” says ASPRS President Paul Schnur, MD. “Women are comfortable about the safety of their breast implants so as their implants age, we will continue to see more implant exchanges.”

Currently, most women receive implants consisting of silicone rubber shells that are filled with sterile saltwater. In this study, 93% of implants were removed due to physical symptoms, such as signs of rupture or capsular contracture. “If a saline implant leaks or ruptures, the saltwater is harmlessly absorbed by the body and the implant is removed and replaced,” says Dr. Schnur.

Other reasons for removal of the implants included capsular contracture (ie, a hardening of the breast due to tightening of the scar or capsule around the implant). This study also found that 53% of patients whose breast implants were removed required removal or scoring of scar tissue.

Related Videos
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
Eric Singhi, MD, and the Oncology Brothers presenting slides
Related Content